Uncategorized, Weight Loss Peptides
MK-677 (Ibutamoren): Complete Research Guide for 2026
MK-677 (Ibutamoren): Complete Research Guide for 2026
MK-677, also known as ibutamoren, is an orally active growth hormone secretagogue that has attracted sustained research interest for its ability to stimulate growth hormone (GH) and insulin-like growth factor-1 (IGF-1) release. Unlike injectable peptides that require reconstitution and frequent administration, MK-677 is a small-molecule ghrelin mimetic taken orally, making it one of the most convenient compounds in the growth hormone axis research space. This guide examines its mechanism, research applications, dosing, side effects, and how it compares to traditional GHRP peptides.
1. What Is MK-677?
MK-677 (ibutamoren mesylate) was developed in the 1990s by Merck as a non-peptide, orally bioavailable growth hormone secretagogue. It belongs to the class of ghrelin receptor (GHSR-1a) agonists, designed to mimic the natural hunger hormone ghrelin’s ability to stimulate GH secretion.
- Molecular formula: C₂₇H₃₆N₄O₅S
- Molecular weight: 528.66 g/mol
- Administration: Oral (tablet or liquid suspension)
- Bioavailability: High oral bioavailability (~60-80%)
- Half-life: Approximately 4-6 hours, but GH-stimulating effects persist much longer
- Status: Research compound; not FDA-approved for any indication
2. Mechanism of Action
MK-677 exerts its effects primarily through the growth hormone secretagogue receptor type 1a (GHSR-1a), the same receptor activated by ghrelin and by GHRP peptides like GHRP-2, GHRP-6, and ipamorelin.
Key mechanistic features:
- GHSR-1a agonism: Directly stimulates the pituitary to release growth hormone pulses
- Hypothalamic interaction: Increases GH-releasing hormone (GHRH) output and may suppress somatostatin tone
- IGF-1 elevation: Sustained GH release translates into increased hepatic IGF-1 production, the primary downstream effector of GH
- Appetite stimulation: Ghrelin receptor activation increases hunger signals via neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons
- Deep sleep enhancement: Increases slow-wave sleep, which itself is associated with endogenous GH release
The most important distinction from injectable GHRPs: MK-677 produces a more sustained, round-the-clock elevation of GH and IGF-1 rather than discrete post-injection pulses. Long-term studies (12 months) have confirmed persistent IGF-1 elevation without tachyphylaxis (diminishing response).
3. Research Applications
3.1 Muscle Mass and Body Composition
MK-677 has been studied for its effects on lean body mass and fat metabolism:
- Preserves and may increase lean body mass in hypogonadal men and elderly populations
- Reduces visceral adiposity in some studies, though less dramatically than GLP-1-based peptides
- May enhance recovery by increasing protein synthesis signaling through IGF-1
- Studies in healthy older adults showed increased fat-free mass over 12 months
3.2 Bone Density and Fracture Recovery
One of the most promising research areas for MK-677 is skeletal health:
- Increases bone turnover markers, indicating active remodeling
- Studies in hip fracture patients showed accelerated recovery and reduced rehabilitation time
- Potential for osteoporosis research given IGF-1’s anabolic effects on bone
3.3 Sleep Quality
MK-677 consistently demonstrates sleep-related effects:
- Increases slow-wave (deep) sleep duration
- May improve sleep architecture in older adults with age-related sleep decline
- GH release during sleep is amplified, potentially improving overnight recovery
3.4 Appetite and Cachexia Research
Because MK-677 stimulates ghrelin receptors, it is studied for conditions involving appetite loss:
- Cancer cachexia and anorexia research
- Age-related sarcopenia and frailty protocols
- Recovery nutrition during catabolic states
4. Dosing Protocols
MK-677 dosing in research settings is well established:
| Protocol | Dose | Timing |
|---|---|---|
| Standard | 10-25 mg/day | Once daily, typically evening |
| Common research dose | 15-20 mg/day | Evening, 30-60 min before sleep |
| Cycling | 8-16 weeks on | Followed by 4-8 weeks off |
Key dosing considerations:
- Evening dosing aligns with natural GH secretion rhythms and minimizes daytime appetite effects
- Consistent daily dosing is required; IGF-1 levels build gradually over 2-4 weeks
- Cycling is commonly used to manage potential insulin resistance and allow metabolic reset
- Some researchers use 5 days on / 2 days off to reduce receptor desensitization concerns
5. MK-677 vs Injectable GHRP Peptides
| Parameter | MK-677 | GHRP-2 / GHRP-6 / Ipamorelin |
|---|---|---|
| Administration | Oral | Subcutaneous injection |
| GH profile | Sustained elevation | Acute post-injection pulses |
| IGF-1 elevation | Strong, cumulative | Moderate |
| Appetite effect | Pronounced | Mild to moderate |
| Convenience | High | Requires reconstitution |
| Insulin sensitivity | Can decrease (watch glucose) | Generally neutral |
| Prolactin/cortisol | Minimal effect | GHRP-6 may raise both |
For researchers prioritizing convenience and sustained IGF-1 exposure, MK-677 is often preferred. For those requiring precise, pulsatile GH stimulation or avoiding appetite increases, injectable GHRPs like ipamorelin may be more appropriate.
6. Side Effects and Considerations
- Increased appetite: The most commonly reported effect; can complicate weight-management protocols
- Fluid retention: Mild peripheral edema is reported, typically transient
- Insulin sensitivity changes: Long-term use may reduce insulin sensitivity; fasting glucose monitoring is recommended in research protocols
- Elevated prolactin/cortisol: Generally minimal with MK-677 compared to GHRP-6
- Growth hormone-related effects: Possible joint discomfort or carpal tunnel-like symptoms at higher doses
7. Frequently Asked Questions
Is MK-677 a peptide? Strictly speaking, no — MK-677 is a small-molecule ghrelin mimetic, not a peptide. However, it operates in the same growth hormone research niche and is frequently grouped with GHRP peptides.
How long until IGF-1 levels rise? Most research protocols show measurable IGF-1 increases within 1-2 weeks, with full effect by 4-6 weeks of daily dosing.
Can MK-677 be stacked with other peptides? Yes. Common research stacks combine MK-677 with GHRH analogs like CJC-1295 no DAC or with recovery peptides such as BPC-157. See our peptide stacking guide for details.
Related Reading
- Growth Hormone Releasing Peptides Complete Guide
- CJC-1295 + Ipamorelin Stack Guide
- Peptides for Athletic Performance Guide
- Peptide Storage & Handling Guide
Shop Related Research Compounds
Browse our research catalog, including CJC-1295 with DAC, CJC-1295 + Ipamorelin blend, and ipamorelin, all supplied with batch COAs.
Disclaimer: This article is for educational and research purposes only. MK-677 is a research compound not approved for human consumption. Always consult qualified professionals regarding research protocols.
